Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Ureteral Neoplasms × Electroporation × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 13 Prostatic Neoplasms 8 Carcinoma, Hepatocellular 7 Liver Neoplasms 5 Neoplasm Metastasis 3 Lung Neoplasms 3 Head and Neck Neoplasms 3 Colorectal Neoplasms 3 Unresectable Pancreatic Cancer 2 Stomach Neoplasms 2 Squamous Intraepithelial Lesions 2 Neoplasms 2 Melanoma 2 Lymphatic Metastasis 2 Locally Advanced Pancreatic Cancer 2 Cholangiocarcinoma 2 Carcinoma, Renal Cell 2 Uterine Cervical Neoplasms 1 Uterine Cervical Dysplasia 1 Urinary Bladder Neoplasms 1 Ureteral Neoplasms 1 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Skin Neoplasms 1 Rectal Neoplasms 1 Pancreatic Ductal Adenocarcinoma 1 Pancreatic Adenocarcinoma Resectable 1 Liver, Cancer of, Non-Resectable 1 Liver Metastasis Colon Cancer 1

Interventions

Gemcitabine 11 Specimen Handling 9 pembrolizumab 7 enfortumab vedotin 7 Magnetic Resonance Spectroscopy 7 Cisplatin 7 Carboplatin 5 vinflunine 4 avelumab 4 Immunoglobulin G 3 Disulfides 3 Biopsy 3 eribulin 2 cabozantinib 2 atezolizumab 2 Standard of Care 2 Ramucirumab 2 Radiotherapy 2 Platinum 2 Nivolumab 2 Nephroureterectomy 2 Ipilimumab 2 Docetaxel 2 CTLA-4 Antigen 2 Bortezomib 2 1,2-diaminocyclohexaneplatinum II citrate 2 vandetanib 1 tremelimumab 1 tocilizumab 1 tamibarotene 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02430779 2021-09-05

IRE

Fuda Cancer Hospital, Guangzhou

Phase NA Completed

Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡